Teva Pharma and Alvotech launch biosimilar to J&J's Stelara in US
Feb 21 (Reuters) - Teva Pharmaceuticals (TEVA.TA), opens new tab and Alvotech (ALVO.O), opens new tab said on Friday they have launched a biosimilar to Johnson & Johnson's (JNJ.N), opens new tab autoimmune drug Stelara in the United States, the second in a wave of near-copies of the blockbuster treatment.
J&J over the past two years has signed settlement agreements with several companies to delay the US launches of Stelara, which has been its top-selling drug since 2019. The first biosimilar, Amgen's (AMGN.O), opens new tab Wezlana, was launched in January this year.
Biocon Biologics (BIOC.NS), opens new tab is set to launch its version of the drug sometime this month, while Fresenius Kabi (FRES.M3), opens new tab is expected to follow with its own launch in April.
Teva and Alvotech's Selarsdi, like Stelara, is approved for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, and moderately to severely active Crohn's disease and ulcerative colitis.
Stelara brought in revenue of $10.36 billion for J&J, making up more than 18% of the drugmaker's total drug sales of $56.96 billion for 2024.
The U.S. Food and Drug Administration has allowed the use of Selarsdi as an "interchangeable" substitute only after April 30, when the exclusive rights for Amgen's Wezlana, expire.
Shares of Teva Pharma rose 2.7% in premarket trading, while Alvotech's saw a 3% increase.
Selarsdi has been launched in Canada as Jamteki, in Europe as Uzpruvo, and in Japan as Ustekinumab BS.
In August 2020, Teva agreed to exclusively market five of Alvotech's biosimilar products in the United States. The companies extended their partnership in 2023 to include two additional biosimilars.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Glasgow Times
2 days ago
- Glasgow Times
Three new cancer drugs approved for use for NHS Scotland
The Scottish Medicines Consortium (SMC) approved the drug brentuximab vedotin, also known as Adcetris, which can be used together with chemotherapy as a first-line treatment for adult patients with advanced Hodgkin lymphoma – an uncommon cancer that develops in the lymphatic system. (Image: Image from PA) SMC vice chair Graeme Bryson said the treatment could 'help increase how long people with advanced Hodgkin lymphoma have before their cancer gets worse'. Meanwhile, zanubrutinib, also known as Brukinsa, was accepted to treat adults with mantle cell lymphoma – a rare type of the blood cancer non-Hodgkin lymphoma. The SMC has also approved the drug ripretinib – also known as Qinlock – to treat adults with advanced gastrointestinal stromal tumours, which are a rare type of cancer of the digestive system. In addition to these drugs it has agreed the NHS can use mirikizumab, also known as Omvoh, for adults with Crohn's disease, a lifelong condition which is a chronic inflammatory bowel disease. READ NEXT: Rock band to play huge headline show in Glasgow Graeme Bryson said: 'The committee is pleased to be able to accept these new medicines for use by NHS Scotland. 'Brentuximab vedotin, used together with chemotherapy, could help increase how long people with advanced Hodgkin lymphoma have before their cancer gets worse. 'Ripretinib provides a fourth-line treatment for advanced gastro-intestinal stromal tumours where currently there is no standard treatment available. 'Zanubrutinib offers an additional oral targeted treatment option for patients with mantle cell lymphoma who have already received one or more lines of treatment. 'Mirikizumab offers an additional treatment option for people with moderate to severe Crohn's disease whose disease is not controlled on standard or biologic treatment.' READ NEXT: Two teens nicked after 'DPD van chased' through streets by cops However, the Scottish Medicines Consortium (SMC) said it could not approve a new treatment for patients with the lung condition chronic obstructive pulmonary disease (COPD) because of a lack of evidence around its cost-effectiveness. It also rejected the drug dupilumab, also known as Dupixent, as a treatment on the NHS for adults with COPD that is controlled on current standard treatments. Bryson said: 'The committee was unable to accept dupilumab for treating patients with COPD as the company's evidence around the cost-effectiveness of the treatment was not sufficient. We would welcome a resubmission from the company.' Joseph Carter, head of the charity Asthma + Lung UK Scotland, added: 'If the cost effectiveness of dupilumab for use by NHS Scotland can be improved, we are hopeful that the Scottish Medicines Consortium will revisit its decision. 'With an estimated 241,000 people living with COPD in Scotland, there is hope that this drug could help guide research for other targeted therapies. 'More lung research is desperately needed to enable a breakthrough to help better control or even cure COPD.'
The National
2 days ago
- The National
Three new cancer drugs approved for use by NHS Scotland
The Scottish Medicines Consortium (SMC) however said it could not approve a new treatment for patients with the lung condition chronic obstructive pulmonary disease (COPD) because of a lack of evidence around its cost-effectiveness. However, the SMC did approve the drug brentuximab vedotin, also known as Adcetris, to be used together with chemotherapy as a first-line treatment for adult patients with advanced Hodgkin lymphoma – an uncommon cancer that develops in the lymphatic system. SMC vice chair Graeme Bryson said the treatment could 'help increase how long people with advanced Hodgkin lymphoma have before their cancer gets worse'. READ MORE: Jewish staff at Scottish universities call for full divestment from Israel Meanwhile, zanubrutinib, also known as Brukinsa, was accepted to treat adults with mantle cell lymphoma – a rare type of the blood cancer non-Hodgkin lymphoma. The SMC has also approved the drug ripretinib – also known as Qinlock – to treat adults with advanced gastrointestinal stromal tumours, which are a rare type of cancer of the digestive system. In addition to these drugs it has agreed the NHS can use mirikizumab, also known as Omvoh, for adults with Crohn's disease, a lifelong condition which is a chronic inflammatory bowel disease. However, the SMC rejected the drug dupilumab, also known as Dupixent, as a treatment on the NHS for adults with COPD that is controlled on current standard treatments. Bryson said: 'The committee is pleased to be able to accept these new medicines for use by NHS Scotland. 'Brentuximab vedotin, used together with chemotherapy, could help increase how long people with advanced Hodgkin lymphoma have before their cancer gets worse. 'Ripretinib provides a fourth-line treatment for advanced gastro-intestinal stromal tumours where currently there is no standard treatment available. 'Zanubrutinib offers an additional oral targeted treatment option for patients with mantle cell lymphoma who have already received one or more lines of treatment. 'Mirikizumab offers an additional treatment option for people with moderate to severe Crohn's disease whose disease is not controlled on standard or biologic treatment.' However he added: 'The committee was unable to accept dupilumab for treating patients with COPD as the company's evidence around the cost-effectiveness of the treatment was not sufficient. We would welcome a resubmission from the company.' Joseph Carter, head of the charity Asthma + Lung UK Scotland, said: 'If the cost effectiveness of dupilumab for use by NHS Scotland can be improved, we are hopeful that the Scottish Medicines Consortium will revisit its decision. 'With an estimated 241,000 people living with COPD in Scotland, there is hope that this drug could help guide research for other targeted therapies. 'More lung research is desperately needed to enable a breakthrough to help better control or even cure COPD.'
STV News
2 days ago
- STV News
Three new cancer drugs approved for use for NHS Scotland
Three new treatments for cancer have been approved for use by the NHS in Scotland. The Scottish Medicines Consortium (SMC) however said it could not approve a new treatment for patients with the lung condition chronic obstructive pulmonary disease (COPD) because of a lack of evidence around its cost-effectiveness. However, the SMC did approve the drug brentuximab vedotin, also known as Adcetris, to be used together with chemotherapy as a first-line treatment for adult patients with advanced Hodgkin lymphoma – an uncommon cancer that develops in the lymphatic system. SMC vice chair Graeme Bryson said the treatment could 'help increase how long people with advanced Hodgkin lymphoma have before their cancer gets worse'. Meanwhile, zanubrutinib, also known as Brukinsa, was accepted to treat adults with mantle cell lymphoma – a rare type of the blood cancer non-Hodgkin lymphoma. The SMC has also approved the drug ripretinib – also known as Qinlock – to treat adults with advanced gastrointestinal stromal tumours, which are a rare type of cancer of the digestive system. In addition to these drugs it has agreed the NHS can use mirikizumab, also known as Omvoh, for adults with Crohn's disease, a lifelong condition which is a chronic inflammatory bowel disease. However, the SMC rejected the drug dupilumab, also known as Dupixent, as a treatment on the NHS for adults with COPD that is controlled on current standard treatments. Mr Bryson said: 'The committee is pleased to be able to accept these new medicines for use by NHS Scotland. 'Brentuximab vedotin, used together with chemotherapy, could help increase how long people with advanced Hodgkin lymphoma have before their cancer gets worse. 'Ripretinib provides a fourth-line treatment for advanced gastro-intestinal stromal tumours where currently there is no standard treatment available. 'Zanubrutinib offers an additional oral targeted treatment option for patients with mantle cell lymphoma who have already received one or more lines of treatment. 'Mirikizumab offers an additional treatment option for people with moderate to severe Crohn's disease whose disease is not controlled on standard or biologic treatment.' However he added: 'The committee was unable to accept dupilumab for treating patients with COPD as the company's evidence around the cost-effectiveness of the treatment was not sufficient. We would welcome a resubmission from the company.' Get all the latest news from around the country Follow STV News Scan the QR code on your mobile device for all the latest news from around the country
